A phase II study of oral piritrexim in recurrent high-grade (III, IV) XXXX .

@entity1 @entity137 @entity5 @entity11 @entity9796 @entity204
Piritrexim is a lipid-soluble drug which is as effective an inhibitor of @entity9796 reductase as methotrexate. Phase I and II studies have indicated activity in some @entity5 types. Because of its lipophilicity we have conducted a phase II study in recurrent high-grade @entity11 (grades III and IV). Twenty-seven @entity1 were treated with 25 mg p.o. three times daily for five consecutive days, repeated weekly, with provision for dose escalation or reduction according to @entity137 . Five @entity1 received less than 4 weeks' treatment because of disease progression or @entity204 . Twenty-two @entity1 were evaluable for response. One complete and one partial response was seen (duration 262+ and 241+ weeks) and 13 @entity1 had static disease for a median duration of 13 weeks (range 7-35). The major @entity137 was myelosuppression. This response rate of 9% of evaluable @entity1 is much lower than that seen for some conventionally used drugs and we conclude that piritrexim is unlikely to be of value in the management of high-grade @entity11 .
